DATASET 2026-08-0941 PROGRAMS INDEXEDTIRZEPATIDE ALL-IN $215–$597/MOEVERY FIGURE CAPTURE-DATED & SOURCE-LINKED
TopGLP1Providers.comverified price index
VERIFIED 2026-08-09

SURMOUNT-5

The randomized head-to-head trial (published NEJM, 2025) comparing tirzepatide and semaglutide at maximum tolerated doses: roughly 20% versus 14% average body-weight reduction at 72 weeks — about 47% greater relative loss for tirzepatide. The single most decision-relevant efficacy datapoint in this category, and a result about the approved products, not compounded copies.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

Seen against the live index: with verified all-in prices spanning $215 to $597 for tirzepatide and $133 to $348 for semaglutide as of 2026-08-09, terms like this one are not pedantry — they are the difference between the advertised number and the billed one. Every definition in this glossary links back to the places in the database and the methodology where the concept does its work.

That ~20% vs ~14% result is why tirzepatide carries a premium in every lane of this index. Related figures live on the pages this term links to, and every one of them regenerates from the same dataset this definition does.

See the term in action across the price database and the methodology.

All-in priceMaintenance-dose basisDose-flat pricingDose-tiered pricingMembership feePrepaid term